The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
EC approval of polatuzumab vedotin in combination with bendamustine and rituximab for R/R DLBCL
On the 21st January 2020, polatuzumab vedotin (pola) in combination with bendamustine and rituximab (BR), was granted conditional marketing authorization by the European Commission (EC), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for a hematopoietic stem cell transplant.1
Pola is a first-in-class antibody-drug conjugate against CD79b, a protein expressed specifically by B cells.2,3 Upon binding, the antibody delivers a cytotoxic dose of microtubule inhibitor, monomethyl auristatin E.
The approval follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation (read here) and was based on the positive results from a multicenter phase Ib/II GO29365 study (NCT02257567) evaluating the efficacy and safety of the combination in R/R DLBCL and FL.3 The results from 80 patients demonstrated superior response rates and overall survival in patients receiving pola-BR compared with BR alone. The interview with Laurie Sehn discussing the results is available here.
In 2019, we reported the accelerated approval for the same indication by the US Food & Drug Administration (FDA). Pola-BR has also received breakthrough therapy designation by the FDA and PRIME (PRIority MEdicines) designation by the EMA for the treatment of patients with R/R DLBCL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content